PCI Biotech progressing positively

The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I in treatment of bilde duct cancer.

Come learn more about cancer

We arrange three seminars during Oslo Innovation Week and Forskningsdagene.

Vi er på Arendalsuka

Jónas Einarsson, administrerende direktør i Radiumhospitalets Forskningsstiftelse skal delta på tre debatter under Arendalsuka. Det er viktige og aktuelle temaer som kliniske studier, et todelt helsevesen og norske kreftpasienters tilgang til den best mulige kreftbehandling, som Einarsson skal være med å debattere. Hør Einarsson her i Arendal:  Sustainable, Innovative Healthcare Tirsdag 15. aug kl 15 […]

Nordic Nanovector: Results from first quarter 2017

Our portfolio company Nordic Nanovector shows  continued progress in clinical development programmes with Betalutin® in their first quarter 2017 presentation.  Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical […]

Photocure: Results for the first quarter 2017

Our portfolio company Photocure reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the […]

Targovax ASA: First quarter 2017 results

Targovax is a clinical stage company focused on developing immuno-oncology therapies to target solid tumors. On april 25th, the company announced its first quarter 2017 results.   HIGHLIGHTS FOR THE FIRST QUARTER 2017: Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer patients – 68%[1] […]